IPAC-RS

PBE Working Group

The objective of this Working Group (WG) is to study the application of the population bioequivalence (PBE) statistical approach, recommended by the FDA, ANVISA and other agencies, for comparing the in-vitro performance of orally inhaled products (Test versus Reference).

Currently, we are establishing data collection methods and designing a database which will, when populated with the specified data,  be used to conduct  a  simulation study.  The simulation study will assess the decision making properties of the PBE statistical approach in the context of in-vitro equivalence of orally inhaled products (Test versus Reference).

Population Bioequivalence Model Working Group Materials

Operating Characteristic (OC) Curves from Simulation

Supplement to Population Bioequivalence Model Working Group Article (2017)

Summary Data for Operating Characteristics Curves from Simulation

News

Modified Chi-Square Ratio (MCSR)

An IPAC-RS collaboration with the University of Florida has been launched.  The group will study the MCSR tests combined with the Population Bioequivalence as recommended by FDA for determination of equivalence in Aerodynamic Particle Size Distributions.

PBE Working Group Update

Population Bioequivalence (PBE) approach has been recommended by FDA and other regulators as an in vitro bioequivalence test for inhaled drugs. The goals of the IPAC-RS PBE Working group are to better understand the performance properties of the PBE statistical method in terms of its use as a decision making tool for assessing equivalency of in vitro manufacturing data. The PBE WG plans to collect data across the industry. Data will be submitted to the group in a blinded fashion, but in a format that will still allow realistic scenarios and simulations to be conducted. The results of this work are intended to be shared through publication to better serve the industry as a whole in developing decision making tools that are fit for purpose for assessing in vitro equivalency. The working group, to date, has identified and agreed a list of inhaled product types and a list of in vitro tests and is currently reviewing a proposed format for collecting blinded data that will serve as the basis for the simulations.

See member benefits

Become an IPAC-RS member today Participation in IPAC-RS affords a variety of benefits including opportunities to shape the scientific and regulatory environment and tools to stay informed.

Sign Up

IPAC-RS members can sign up to receive our monthly update on IPAC-RS and regulatory developments.